Emmaus Life Sciences Equity 2024

Emmaus Life Sciences Aktienanalyse

What does Emmaus Life Sciences do?

Emmaus Life Sciences Inc. is an innovative US-American company that develops, produces, and markets medications based on L-Glutamine. The company was founded in 2000 by Dr. Yutaka Niihara, a Japanese researcher who grew up in the USA and received his doctorate from Harvard Medical School. The idea for founding Emmaus Life Sciences arose from the observation of patients with sickle cell anemia, an inherited blood disease. These patients suffer from intense pain attacks caused by the clumping of red blood cells in the body. Dr. Niihara and his colleagues researched the effects of L-Glutamine on these pain attacks and were able to demonstrate that L-Glutamine can significantly reduce the frequency and intensity of the pain attacks. Based on these research results, Emmaus Life Sciences developed the medication "Endari," which was approved by the US-American regulatory authority FDA in 2017. "Endari" is the first medication specifically approved for the treatment of sickle cell anemia. It is intended to reduce the frequency and severity of pain attacks in patients with sickle cell anemia. Since its founding in 2000, Emmaus Life Sciences has expanded significantly. The company now has multiple locations in the USA and employs over 150 employees. Emmaus Life Sciences operates in two business areas: medications and health products. In the medication area, Emmaus Life Sciences focuses on the development of drugs for rare diseases. In addition to "Endari," the company is working on the development of medications for the treatment of mucopolysaccharidosis (MPS) and acid peptidase deficiency (ASM). In the health products area, Emmaus Life Sciences specializes in the production and marketing of dietary supplements. The company has developed a range of products based on L-Glutamine as the active ingredient. These products are intended to support the health of athletes, people with special dietary needs, older adults, and people with certain diseases. Emmaus Life Sciences' products include L-Glutamine powder for daily use, L-Glutamine capsules for athletes and bodybuilders, L-Glutamine for clinical nutrition, and a special L-Glutamine product for people with chronic kidney disease. Emmaus Life Sciences is an innovative company that builds its products on scientifically validated research results. The company specializes in the development of medications and health products that help people improve their health and increase their quality of life. Emmaus Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Emmaus Life Sciences's Equity

Emmaus Life Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Emmaus Life Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Emmaus Life Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Emmaus Life Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Emmaus Life Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Emmaus Life Sciences stock

What is the equity of Emmaus Life Sciences this year?

Emmaus Life Sciences has equity of -47.76 M USD this year.

What was the equity of Emmaus Life Sciences compared to the previous year?

The equity of Emmaus Life Sciences has increased/decreased by 40.09% increased compared to the previous year.

What impact does a high equity have on investors of Emmaus Life Sciences?

A high equity is advantageous for investors of Emmaus Life Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Emmaus Life Sciences?

A low equity can be a risk for investors of Emmaus Life Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Emmaus Life Sciences affect the company?

An increase in equity of Emmaus Life Sciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Emmaus Life Sciences affect the company?

A reduction in equity of Emmaus Life Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Emmaus Life Sciences?

Some factors that can affect the equity of Emmaus Life Sciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Emmaus Life Sciences so important for investors?

The equity of Emmaus Life Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Emmaus Life Sciences take to change the equity?

To change equity, Emmaus Life Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Emmaus Life Sciences pay?

Over the past 12 months, Emmaus Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emmaus Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Emmaus Life Sciences?

The current dividend yield of Emmaus Life Sciences is .

When does Emmaus Life Sciences pay dividends?

Emmaus Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emmaus Life Sciences?

Emmaus Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Emmaus Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emmaus Life Sciences located?

Emmaus Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emmaus Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emmaus Life Sciences from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Emmaus Life Sciences pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Emmaus Life Sciences in the year 2023?

In the year 2023, Emmaus Life Sciences distributed 0 USD as dividends.

In which currency does Emmaus Life Sciences pay out the dividend?

The dividends of Emmaus Life Sciences are distributed in USD.